Difference between revisions of "WHIM syndrome"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:100%;" !colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors''' |-...")
 
 
(12 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
{| class="wikitable" style="text-align:center; width:100%;"
+
<span id="BackToTop"></span>
−
!colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors'''
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
|-
+
[[#top|Back to Top]]
−
|style="background-color:#F0F0F0; width:15%"|[[File:Shruti.jpg|frameless|upright=0.3|center]]
+
</div>
−
|style="width:35%"|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Johns Hopkins University<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn]
+
{{#lst:Editorial board transclusions|heme}}
−
|style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]]
 
−
|style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big>
 
−
|-
 
−
|}
 
 
'''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis
 
'''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis
−
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 16: Line 11:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
 
 
=All lines of therapy=
 
=All lines of therapy=
−
 
 
==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}==
 
==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}==
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
 
===Regimen {{#subobject:be34d7|Variant=1}}===
 
===Regimen {{#subobject:be34d7|Variant=1}}===
−
{| class="wikitable" style="width: 50%; text-align:center;"  
+
{| class="wikitable" style="width: 40%; text-align:center;"  
 
!style="width: 25%"|Study
 
!style="width: 25%"|Study
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1808575 McDermott et al. 2019]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019]
−
|style="background-color:#ffffbe"|Pilot, <20 pts
+
|style="background-color:#ffffbe"|Pilot, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Growth factor therapy====
 
====Growth factor therapy====
−
*[[Plerixafor (Mozobil)]]
+
*[[Plerixafor (Mozobil)]] 0.01 to 0.02 mg/kg SC twice per day
−
 
+
'''Various durations'''
 +
</div></div>
 
===References===
 
===References===
−
# McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://www.nejm.org/doi/full/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30625055 PubMed]
+
# '''Case series:''' McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/30625055/ PubMed]
−
 
 
 
[[Category:WHIM syndrome regimens]]
 
[[Category:WHIM syndrome regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Cytopenias]]
 
[[Category:Cytopenias]]

Latest revision as of 13:28, 5 November 2023

Back to Top

Section editor
Tillman Benjamin-2.jpg
 Benjamin Tillman, MD
Vanderbilt University
Nashville, TN, USA
LinkedIn

WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis

1 regimens on this page
1 variants on this page


All lines of therapy

Plerixafor monotherapy

Regimen

Study Evidence
McDermott et al. 2019 Pilot, fewer than 20 pts

Growth factor therapy

Various durations

References

  1. Case series: McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article contains dosing details in manuscript PubMed
Retrieved from "https://hemonc.org/w/index.php?title=WHIM_syndrome&oldid=80330"